Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.
BACKGROUND
In Parkinson disease (PD), the benefit of levodopa therapy becomes less marked over time, perhaps because degeneration of nigrostrial neurons causes progressive loss of aromatic l-amino acid decarboxylase (AADC), the enzyme that converts levodopa into dopamine. In a primate model of PD, intrastriatal infusion of an adeno-associated viral type 2 vector containing the human AADC gene (AAV-hAADC) results in robust response to low-dose levodopa without the side effects associated with higher doses. These data prompted a clinical trial.


METHODS
Patients with moderately advanced PD received bilateral intraputaminal infusion of AAV-hAADC vector. Low-dose and high-dose cohorts (5 patients in each) were studied using standardized clinical rating scales at baseline and 6 months. PET scans using the AADC tracer [(18)F]fluoro-L-m-tyrosine (FMT) were performed as a measure of gene expression.


RESULTS
The gene therapy was well tolerated, but 1 symptomatic and 2 asymptomatic intracranial hemorrhages followed the operative procedure. Total and motor rating scales improved in both cohorts. Motor diaries also showed increased on-time and reduced off-time without increased "on" time dyskinesia. At 6 months, FMT PET showed a 30% increase of putaminal uptake in the low-dose cohort and a 75% increase in the high-dose cohort.


CONCLUSIONS
This study provides class IV evidence that bilateral intrastriatal infusion of adeno-associated viral type 2 vector containing the human AADC gene improves mean scores on the Unified Parkinson's Disease Rating Scale by approximately 30% in the on and off states, but the surgical procedure may be associated with an increased risk of intracranial hemorrhage and self-limited headache.
Christine
C W
CW
Department of Neurology, University of California, San Francisco, CA 94143-0114, USA.
Starr
P A
PA
Larson
P S
PS
Eberling
J L
JL
Jagust
W J
WJ
Hawkins
R A
RA
VanBrocklin
H F
HF
Wright
J F
JF
Bankiewicz
K S
KS
Aminoff
M J
MJ
D000368:Aged; D001142:Aromatic-L-Amino-Acid Decarboxylases / Q000235:genetics* / Q000627:therapeutic use*; D015331:Cohort Studies; D020820:Dyskinesias / Q000503:physiopathology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D015316:Genetic Therapy / Q000009:adverse effects; D006801:Humans; D020300:Intracranial Hemorrhages / Q000209:etiology; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures / Q000009:adverse effects; D010300:Parkinson Disease / Q000503:physiopathology* / Q000601:surgery / Q000628:therapy*; D049268:Positron-Emission Tomography; D011699:Putamen / Q000000981:diagnostic imaging / Q000503:physiopathology* / Q000601:surgery; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D001142:Aromatic-L-Amino-Acid Decarboxylases